This HTML5 document contains 187 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n31http://www.rxlist.com/cgi/generic3/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n32http://linked.opendata.cz/resource/AHFS/
n8http://linked.opendata.cz/resource/mesh/concept/
n10http://linked.opendata.cz/resource/drugbank/company/
foafhttp://xmlns.com/foaf/0.1/
n28http://linked.opendata.cz/resource/drugbank/drug/DB01039/identifier/pharmgkb/
n6http://linked.opendata.cz/resource/drugbank/drug/DB01039/identifier/wikipedia/
n9http://linked.opendata.cz/resource/drugbank/dosage/
n21http://linked.opendata.cz/resource/drugbank/drug/DB01039/identifier/kegg-compound/
n29http://linked.opendata.cz/resource/drugbank/drug/DB01039/identifier/pubchem-compound/
n13http://www.drugs.com/
n30http://bio2rdf.org/drugbank:
n27http://linked.opendata.cz/resource/drugbank/drug/DB01039/identifier/pubchem-substance/
n19http://linked.opendata.cz/resource/drugbank/drug/DB01039/identifier/kegg-drug/
n17http://linked.opendata.cz/resource/drugbank/drug/DB01039/identifier/drugbank/
admshttp://www.w3.org/ns/adms#
n15http://linked.opendata.cz/resource/drugbank/patent/
n23http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n26http://linked.opendata.cz/resource/drugbank/medicinal-product/
n20http://linked.opendata.cz/resource/drugbank/drug/DB01039/identifier/national-drug-code-directory/
n7http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
n14http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/
xsdhhttp://www.w3.org/2001/XMLSchema#
n16http://linked.opendata.cz/resource/drugbank/drug/DB01039/identifier/chemspider/
n18http://linked.opendata.cz/resource/drugbank/drug/DB01039/identifier/chebi/
n25http://linked.opendata.cz/resource/atc/
n24http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01039
rdf:type
n3:Drug
n3:description
An antilipemic agent which reduces both cholesterol and triglycerides in the blood. [PubChem]
n3:dosage
n9:271B581C-363D-11E5-9242-09173F13E4C5 n9:271B581D-363D-11E5-9242-09173F13E4C5 n9:271B581E-363D-11E5-9242-09173F13E4C5 n9:271B581F-363D-11E5-9242-09173F13E4C5 n9:271B5820-363D-11E5-9242-09173F13E4C5 n9:271B5821-363D-11E5-9242-09173F13E4C5 n9:271B581A-363D-11E5-9242-09173F13E4C5 n9:271B581B-363D-11E5-9242-09173F13E4C5 n9:271B5822-363D-11E5-9242-09173F13E4C5 n9:271B5823-363D-11E5-9242-09173F13E4C5 n9:271B5824-363D-11E5-9242-09173F13E4C5 n9:271B5834-363D-11E5-9242-09173F13E4C5 n9:271B5835-363D-11E5-9242-09173F13E4C5 n9:271B5836-363D-11E5-9242-09173F13E4C5 n9:271B5818-363D-11E5-9242-09173F13E4C5 n9:271B5828-363D-11E5-9242-09173F13E4C5 n9:271B5829-363D-11E5-9242-09173F13E4C5 n9:271B582A-363D-11E5-9242-09173F13E4C5 n9:271B582B-363D-11E5-9242-09173F13E4C5 n9:271B5819-363D-11E5-9242-09173F13E4C5 n9:271B5825-363D-11E5-9242-09173F13E4C5 n9:271B5826-363D-11E5-9242-09173F13E4C5 n9:271B5827-363D-11E5-9242-09173F13E4C5 n9:271B5830-363D-11E5-9242-09173F13E4C5 n9:271B5831-363D-11E5-9242-09173F13E4C5 n9:271B5832-363D-11E5-9242-09173F13E4C5 n9:271B5833-363D-11E5-9242-09173F13E4C5 n9:271B582C-363D-11E5-9242-09173F13E4C5 n9:271B582D-363D-11E5-9242-09173F13E4C5 n9:271B582E-363D-11E5-9242-09173F13E4C5 n9:271B582F-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Wysocki J, Belowski D, Kalina M, Kochanski L, Okopien B, Kalina Z: Effects of micronized fenofibrate on insulin resistance in patients with metabolic syndrome. Int J Clin Pharmacol Ther. 2004 Apr;42(4):212-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15124979 # Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesaniemi YA, Sullivan D, Hunt D, Colman P, d'Emden M, Whiting M, Ehnholm C, Laakso M: Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005 Nov 26;366(9500):1849-61. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16310551
n3:group
approved
n3:halfLife
20 hours
n3:indication
For use as adjunctive therapy to diet to reduce elevated LDL-C, Total-C,Triglycerides and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb)
owl:sameAs
n23:DB01039 n30:DB01039
dcterms:title
Fenofibrate
adms:identifier
n6:Fenofibrate n16:3222 n17:DB01039 n18:5001 n19:D00565 n20:0378-7100-77 n21:C07586 n27:46507371 n28:PA449594 n29:3339
n3:mechanismOfAction
Fenofibrate exerts its therapeutic effects through activation of peroxisome proliferator activated receptor a (PPARa). This increases lipolysis and elimination of triglyceride-rich particles from plasma by activating lipoprotein lipase and reducing production of apoprotein C-III. The resulting fall in triglycerides produces an alteration in the size and composition of LDL from small, dense particles, to large buoyant particles. These larger particles have a greater affinity for cholesterol receptors and are catabolized rapidly.
n3:packager
n10:271B57DD-363D-11E5-9242-09173F13E4C5 n10:271B57DE-363D-11E5-9242-09173F13E4C5 n10:271B57DB-363D-11E5-9242-09173F13E4C5 n10:271B57DC-363D-11E5-9242-09173F13E4C5 n10:271B57D9-363D-11E5-9242-09173F13E4C5 n10:271B57DA-363D-11E5-9242-09173F13E4C5 n10:271B57D7-363D-11E5-9242-09173F13E4C5 n10:271B57D8-363D-11E5-9242-09173F13E4C5 n10:271B57D5-363D-11E5-9242-09173F13E4C5 n10:271B57D6-363D-11E5-9242-09173F13E4C5 n10:271B57D3-363D-11E5-9242-09173F13E4C5 n10:271B57D4-363D-11E5-9242-09173F13E4C5 n10:271B57D1-363D-11E5-9242-09173F13E4C5 n10:271B57D2-363D-11E5-9242-09173F13E4C5 n10:271B57CF-363D-11E5-9242-09173F13E4C5 n10:271B57D0-363D-11E5-9242-09173F13E4C5 n10:271B57F0-363D-11E5-9242-09173F13E4C5 n10:271B57F1-363D-11E5-9242-09173F13E4C5 n10:271B57EB-363D-11E5-9242-09173F13E4C5 n10:271B57EC-363D-11E5-9242-09173F13E4C5 n10:271B57E9-363D-11E5-9242-09173F13E4C5 n10:271B57EA-363D-11E5-9242-09173F13E4C5 n10:271B57E7-363D-11E5-9242-09173F13E4C5 n10:271B57E8-363D-11E5-9242-09173F13E4C5 n10:271B57E5-363D-11E5-9242-09173F13E4C5 n10:271B57E6-363D-11E5-9242-09173F13E4C5 n10:271B57E3-363D-11E5-9242-09173F13E4C5 n10:271B57E4-363D-11E5-9242-09173F13E4C5 n10:271B57E1-363D-11E5-9242-09173F13E4C5 n10:271B57E2-363D-11E5-9242-09173F13E4C5 n10:271B57DF-363D-11E5-9242-09173F13E4C5 n10:271B57E0-363D-11E5-9242-09173F13E4C5 n10:271B57EF-363D-11E5-9242-09173F13E4C5 n10:271B57ED-363D-11E5-9242-09173F13E4C5 n10:271B57EE-363D-11E5-9242-09173F13E4C5 n10:271B57CD-363D-11E5-9242-09173F13E4C5 n10:271B57CE-363D-11E5-9242-09173F13E4C5
n3:patent
n15:2219475 n15:7569612 n15:2487054 n15:5145684
n3:routeOfElimination
Fenofibric acid is primarily conjugated with glucuronic acid and then excreted in urine. Following oral administration in healthy volunteers, approximately 60% of a single dose of radiolabelled fenofibrate appeared in urine, primarily as fenofibric acid and its glucuronate conjugate and 25% was excreted in the feces.
n3:synonym
2-(4-(4-Chlorobenzoyl)phenoxy)-2-methylpropanoic acid 1-methylethyl ester Procetofen Isopropyl (4'-(P-chlorobenzoyl)-2-phenoxy-2-methyl)propionate Lipantil (tn) Fenofibratum Isopropyl 2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropionate Tricor (tn) Finofibrate Fenofibrate FNF Fenofibric acid Fenofibrato
n3:toxicity
LD<sub>50</sub>=1600 mg/kg (Oral, in mice); Investigated as a teratogen and reproductive hazard.
n3:volumeOfDistribution
* 95 L [moderate renal impairment (creatinine clearance of 50 to 90 mL/min)] * 30 L [healthy adults]
n24:hasAHFSCode
n32:24-06-06
n3:foodInteraction
Increased absorption- take with meals.
n3:proteinBinding
~99% (Serum protein binding)
n3:synthesisReference
Jean-Francois Boyer, "Medicine based on fenofibrate, and a method of preparing it." U.S. Patent US4800079, issued January, 1988.
n7:hasConcept
n8:M0017618
foaf:page
n13:fenofibrate.html n14:cx1550.shtml n31:fenofibrate.htm
n3:IUPAC-Name
n4:271B583B-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B5841-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B5840-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B583D-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B583E-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B583F-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B5839-363D-11E5-9242-09173F13E4C5 n4:271B5850-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B5837-363D-11E5-9242-09173F13E4C5 n4:271B583A-363D-11E5-9242-09173F13E4C5 n4:271B5852-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B5838-363D-11E5-9242-09173F13E4C5
n24:hasATCCode
n25:C10AB05
n3:H-Bond-Acceptor-Count
n4:271B5847-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B5848-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B5842-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B5843-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B5845-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B5844-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B5846-363D-11E5-9242-09173F13E4C5
n3:absorption
Fenofibrate is well absorbed from the gastrointestinal tract. After absorption, fenofibrate is mainly excreted in the urine in the form of metabolites, primarily fenofibric acid and fenofibric acid glucuronide
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
49562-28-9
n3:category
n3:clearance
* 1.2 L/h [Eldery]
n3:containedIn
n26:271B5806-363D-11E5-9242-09173F13E4C5 n26:271B5807-363D-11E5-9242-09173F13E4C5 n26:271B5816-363D-11E5-9242-09173F13E4C5 n26:271B5804-363D-11E5-9242-09173F13E4C5 n26:271B5813-363D-11E5-9242-09173F13E4C5 n26:271B5817-363D-11E5-9242-09173F13E4C5 n26:271B5805-363D-11E5-9242-09173F13E4C5 n26:271B5814-363D-11E5-9242-09173F13E4C5 n26:271B5811-363D-11E5-9242-09173F13E4C5 n26:271B5802-363D-11E5-9242-09173F13E4C5 n26:271B5812-363D-11E5-9242-09173F13E4C5 n26:271B5803-363D-11E5-9242-09173F13E4C5 n26:271B580F-363D-11E5-9242-09173F13E4C5 n26:271B5800-363D-11E5-9242-09173F13E4C5 n26:271B5810-363D-11E5-9242-09173F13E4C5 n26:271B5801-363D-11E5-9242-09173F13E4C5 n26:271B57FE-363D-11E5-9242-09173F13E4C5 n26:271B57FF-363D-11E5-9242-09173F13E4C5 n26:271B5815-363D-11E5-9242-09173F13E4C5 n26:271B580D-363D-11E5-9242-09173F13E4C5 n26:271B580E-363D-11E5-9242-09173F13E4C5 n26:271B580B-363D-11E5-9242-09173F13E4C5 n26:271B57FC-363D-11E5-9242-09173F13E4C5 n26:271B580C-363D-11E5-9242-09173F13E4C5 n26:271B57FD-363D-11E5-9242-09173F13E4C5 n26:271B57FA-363D-11E5-9242-09173F13E4C5 n26:271B5809-363D-11E5-9242-09173F13E4C5 n26:271B580A-363D-11E5-9242-09173F13E4C5 n26:271B57FB-363D-11E5-9242-09173F13E4C5 n26:271B57F8-363D-11E5-9242-09173F13E4C5 n26:271B57F9-363D-11E5-9242-09173F13E4C5 n26:271B5808-363D-11E5-9242-09173F13E4C5 n26:271B57F6-363D-11E5-9242-09173F13E4C5 n26:271B57F7-363D-11E5-9242-09173F13E4C5 n26:271B57F4-363D-11E5-9242-09173F13E4C5 n26:271B57F5-363D-11E5-9242-09173F13E4C5 n26:271B57F2-363D-11E5-9242-09173F13E4C5 n26:271B57F3-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B584C-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B584E-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B584F-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B5851-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B584B-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B584A-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B584D-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B583C-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B5849-363D-11E5-9242-09173F13E4C5